For the quarter ending 2025-09-30, CLSD made $201K in revenue. -$5,972K in net income. Net profit margin of -2971.14%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| License and other revenue (includes 171 and 81 from a related party for the three months ended september 30, 2025 and 2024, respectively, and 655and 237 for the nine months ended september 30, 2025 and 2024, respectively) | 201 | 492 | 2,330 | -1,450* |
| Cost of goods sold | 0 | 0 | 248 | 37* |
| Research and development (includes 255 and 473 to a related party for the three and nine months ended september 30, 2024, respectively) | 2,933 | 1,584 | 4,463 | 52,428* |
| General and administrative | 4,308 | 2,476 | 2,824 | 3,275* |
| Total operating expenses | 7,241 | 4,060 | 7,535 | 55,740* |
| Loss from operations | -7,040 | -3,568 | -5,205 | -57,190* |
| Other income, net | - | - | - | 1,752* |
| Interest income | 65 | 115 | 163 | 448* |
| Other income, net | 3,573 | 1,720 | 207 | - |
| Non-cash interest expense on liability related to the sales of future royalties | 2,570 | 2,762 | 2,673 | 2,408* |
| Loss before income taxes | -5,972 | -4,495 | -7,508 | - |
| Income tax expense | 0 | 0 | 715 | - |
| Net loss | -5,972 | -4,495 | -8,223 | -57,398 |
| Basic EPS | -1.14 | -0.06 | -0.11 | -0.788 |
| Diluted EPS | -1.14 | -0.06 | -0.11 | -0.788 |
| Basic Average Shares | 5,233,981 | 77,844,055 | 76,921,843 | 72,861,281 |
| Diluted Average Shares | 5,233,981 | 77,844,055 | 76,921,843 | 72,861,281 |
Clearside Biomedical, Inc. (CLSD)
Clearside Biomedical, Inc. (CLSD)